Lupin Receives FDA Approval for Potassium Chloride Extended-Release Capsules

Lupin Limited's US subsidiary, Gavis Pharmaceuticals LLC., U.S.A. (collectively Lupin) has received final approval for its Potassium Chloride ExtendedRelease Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (FDA) to market a generic equivalent of Actavis Labs FL, Inc's Potassium Chloride ExtendedRelease Capsules USP, 8 mEq and 10 mEq.

Lupin's Potassium Chloride Extended-Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) are the AB rated generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended-Release Capsules USP, 8 mEq and 10 mEq. It is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications and in patients with hypokalemic familial periodic paralysis. It is also indicated for the prevention of hypokalemia in patients who would be at a particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.

Potassium Chloride Extended-Release Capsules USP, 8 mEq and 10 mEq had US sales of USD 75.4 million (IMS MAT June 2016).

Shares of LUPIN LTD. was last trading in BSE at Rs.1589.9 as compared to the previous close of Rs. 1595.3. The total number of shares traded during the day was 54607 in over 2512 trades.

The stock hit an intraday high of Rs. 1607.65 and intraday low of 1582.5. The net turnover during the day was Rs. 87147319.

Source : Equity Bulls

Keywords